Clinical significance of microRNA expression in patients with Epstein-Barr virus associated gastric cancer

Date

08 Oct 2016

Session

Poster Display

Presenters

Jong Gwang Kim

Citation

Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371

Authors

J.G. Kim1, B.W. Kang1, Y.S. Chae1, S.J. Lee1, J.H. Baek2

Author affiliations

  • 1 Oncology/hematology, Kyungpook National University Medical Center, 41404 - Daegu/KR
  • 2 Hematology/oncology, Ulsan University Hospital, 4033 - Ulsan/KR
More

Resources

Background

Previous reports have shown that the expression of miRNA was involved in the development or prognosis of Epstein-Barr virus associated gastric cancer (EBVaGC). Therefore, the expression or target genes of the EBV miRNA can be useful as biomarker for EBVaGC. This study investigated the clinical significance of EBV miRNA expressions in patients with EBVaGC.

Methods

After reviewing 1318 consecutive cases of surgically resected or endoscopic submucosal dissected gastric cancers, 120 patients were identified as EBV-positive using EBV-encoded RNA in-situ hybridization. Among the 120 patients, the miRNA expression was examined in 39 tumor and 39 paired normal mucosal tissues from available formalin-fixed paraffin embedded tissues. The ebv-miRNAs expression levels for ebv-miR-BART1-5p, ebv-miR-BART4-5p, and ebv-miR-BART20-5p were determined by quantitative real-time PCR and the data were normalized relative to U6 expression. The average value of ebv-miRNAs expression levels was used as the cutoff point.

Results

The median age of the patients was 64 years (40-76) and 31 (79.5%) were male. The pathologic stages after surgical resection were as follows: stage I (n = 13), stage II (n = 12), and stage III (n = 14). The expression of these miRNAs was significantly higher in tumor tissue than paired normal tissue (P 

Conclusions

The ebv-miR-BART1-5p, ebv-miR-BART4-5p, and ebv-miR-BART20-5p were highly expressed in EBVaGC tissues, and the expression level of ebv-miR-BART20-5p may predict RFS for patients with EBVaGC. Further studies are warranted to elucidate the roles of EBV miRNAs in carcinogenesis of EBVaGC, which would be a potential therapeutic target.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

Ministry of Health & Welfare, Korea

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings